Cancer Research Targets  Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, X.
Right arrow Articles by Stanley, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, X.
Right arrow Articles by Stanley, P.
[Cancer Research 60, 3313-3319, June 15, 2000]
© 2000 American Association for Cancer Research


Tumor Biology

New Evidence for an Extra-Hepatic Role of N-acetylglucosaminyltransferase III in the Progression of Diethylnitrosamine-induced Liver Tumors in Mice1

Xiaoping Yang, Mantu Bhaumik, Riddhi Bhattacharyya, Shih Gong, Charles E. Rogler and Pamela Stanley2

Departments of Cell Biology [X. Y., M. B., R. B., P. S.] and Medicine and Microbiology/Immunology [S. G., C. E. R.], Albert Einstein College of Medicine, New York, New York 10461

N-acetylglucosaminyltransferase III (GlcNAc-TIII) is encoded by the Mgat3 gene and catalyzes the addition of the bisecting GlcNAc to the core of N-glycans. Mice lacking GlcNAc-TIII due to the insertion mutation Mgat3tm1Pst (termed Mgat3neo), exhibit retarded progression of liver tumors induced by diethylnitrosamine (DEN; M. Bhaumik et al., Cancer Res., 58: 2881–2887, 1998). This phenotype seemed to be due to a reduction, in activity or amount, of a circulating glycoprotein(s) that enhances DEN-induced liver tumor progression. Here, we provide new evidence to support this hypothesis. First, we show that mice with a deletion mutation of the Mgat3 gene coding exon (Mgat3tmlJxm, termed Mgat3{Delta}) also exhibit retarded progression of DEN-induced liver tumors. At 7 months there was a significant decrease in liver weight (~27%; P < 0.01), reflecting reduced tumor burden in Mgat3{Delta}/{Delta} mice. In addition, tumors were generally fewer and smaller, and histological changes were less severe in Mgat3{Delta}/{Delta} livers. Therefore, tumor progression is retarded in mice with two different null mutations in the Mgat3 gene. Second, we show that the development of DEN-induced tumors is unaltered by high levels of GlcNAc-TIII in the liver of transgenic mice. The Mgat3 gene coding exon under the control of the major urinary protein (MUP) promoter was used to generate transgenic mice that express GlcNAc-TIII in liver. Following DEN injection and phenobarbitol treatment, however, no significant differences were observed between MUP/Mgat3 transgenic and control mice in either tumor numbers or liver weight. The combined data provide strong evidence that retarded progression of tumors in mice lacking GlcNAc-TIII is due to the absence of the bisecting GlcNAc residue on N-glycans of a circulating glycoprotein(s) from a tissue other than liver.




This article has been cited by other articles:


Home page
J. Gen. Virol.Home page
G. Tamguney, K. Giles, D. V. Glidden, P. Lessard, H. Wille, P. Tremblay, D. F. Groth, F. Yehiely, C. Korth, R. C. Moore, et al.
Genes contributing to prion pathogenesis
J. Gen. Virol., July 1, 2008; 89(7): 1777 - 1788.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
P. Stanley, S. Sundaram, J. Tang, and S. Shi
Molecular analysis of three gain-of-function CHO mutants that add the bisecting GlcNAc to N-glycans
Glycobiology, January 1, 2005; 15(1): 43 - 53.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Yang, J. Tang, C. E. Rogler, and P. Stanley
Reduced Hepatocyte Proliferation is the Basis of Retarded Liver Tumor Progression and Liver Regeneration in Mice Lacking N-Acetylglucosaminyltransferase III
Cancer Res., November 15, 2003; 63(22): 7753 - 7759.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Kui Wong, R. L. Easton, M. Panico, M. Sutton-Smith, J. C. Morrison, F. A. Lattanzio, H. R. Morris, G. F. Clark, A. Dell, and M. S. Patankar
Characterization of the Oligosaccharides Associated with the Human Ovarian Tumor Marker CA125
J. Biol. Chem., August 1, 2003; 278(31): 28619 - 28634.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Bhattacharyya, M. Bhaumik, T. S. Raju, and P. Stanley
Truncated, Inactive N-Acetylglucosaminyltransferase III (GlcNAc-TIII) Induces Neurological and Other Traits Absent in Mice That Lack GlcNAc-TIII
J. Biol. Chem., July 12, 2002; 277(29): 26300 - 26309.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Sato, M. Takahashi, Y. Shibukawa, S. K. Jain, R. Hamaoka, J.-i. Miyagawa, Y. Yaginuma, K. Honke, M. Ishikawa, and N. Taniguchi
Overexpression of N-Acetylglucosaminyltransferase III Enhances the Epidermal Growth Factor-induced Phosphorylation of ERK in HeLaS3 Cells by Up-regulation of the Internalization Rate of the Receptors
J. Biol. Chem., April 6, 2001; 276(15): 11956 - 11962.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.